Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Health Catalyst Inc. (HCAT:NASDAQ), powered by AI.
Health Catalyst Inc. is currently trading at $1.94. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Health Catalyst Inc. on Alpha Lenz.
Health Catalyst Inc.'s P/E ratio is -0.8.
“Health Catalyst Inc. trades at a P/E of -0.8 (undervalued) with modest ROE of -58.3%.”
Ask for details →Health Catalyst Inc. is a technology company that provides data and analytics solutions to healthcare organizations. Its primary function is to help healthcare providers improve clinical and financial outcomes by leveraging data-driven insights. The company offers a comprehensive software platform known as Data Operating System (DOS), which aggregates and analyzes vast amounts of healthcare data. This platform supports a range of applications, including quality improvement, patient safety, and operational efficiency. Health Catalyst Inc. serves various sectors within the healthcare industry, including hospitals, physician practices, and health systems. The solutions provided by Health Catalyst aim to enhance decision-making processes by providing actionable insights that help reduce costs, improve patient care, and streamline operations. In the financial market, Health Catalyst Inc. is recognized for its vital role in the digital transformation of healthcare, marked by its innovative approach to utilizing big data. As healthcare systems increasingly adopt technological solutions to optimize their practices, Health Catalyst stands as a significant player, enabling institutions to harness the power of data to achieve better outcomes.
“Health Catalyst Inc. trades at a P/E of -0.8 (undervalued) with modest ROE of -58.3%.”
Ask for details →Health Catalyst Inc. (ticker: HCAT) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 1,500 employees. Market cap is $136M.
The current price is $1.94 with a P/E ratio of -0.76x and P/B of 0.55x.
ROE is -58.26% and operating margin is -13.74%. Annual revenue is $311M.